FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to ophthalmology and can be used for treatment of glaucoma or higher intraocular pressure (IOP) in patient. For this purpose efficient amount of composition, containing preparation inhibiting PAI-1 binding with vitronectin, is introduced to patient. Also claimed is method of treating PAI-1-associated eye disease.
EFFECT: group of inventions ensures treatment of glaucoma and IOP due to reduction of separation of trabecular meshwork tissue and reduction of increased resistance to intraocular fluid outflow, and also due to increase of TM tissue cellularity and preservation of phagocytosis.
14 cl, 8 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTAGONISTS CDK2 AS ANTAGONISTS OF SHORT FORM OF C-MAF TRANSCRIPTION FACTOR FOR GLAUCOMA TREATMENT | 2004 |
|
RU2370267C2 |
| AGENTS ADJUSTING, INHIBITING OR MODULATING ACTIVITY AND/OR EXPRESSION OF CONNECTIVE TISSUE GROWTH FACTORS (CTGF) AS UNIQUE DRUGS FOR INTRAOCULAR TENSION REDUCTION AND TREATMENT OF GLAUCOMA RETINOPATHIES/OPTICAL NEUROPATHIES | 2003 |
|
RU2332213C2 |
| MEDIATED PHKi INHIBITION OF Rho-KINASE FOR TREATING OPHTHALMIC DISORDERS | 2006 |
|
RU2432165C2 |
| NOVEL NRP-B AGONISTS | 2010 |
|
RU2557290C2 |
| NEW NPR-B AGONISTS | 2010 |
|
RU2636738C2 |
| APPLICATION OF SERUM AMYLOID A GENE FOR DIAGNOSIS AND THERAPY OF GLAUCOMA AND IDENTIFICATION OF ANTIGLAUCOMATOUS AGENT | 2007 |
|
RU2461378C2 |
| siPHK-BASED TREATMENT OF EYE DISEASE CHARACTERISED BY HIGH INTRAOCULAR PRESSURE | 2005 |
|
RU2407531C2 |
| APPLICATION OF SERUMAL AMYLOID GENE A IN DIAGNOSTICS AND TREATMENT OF GLAUCOMA AND DETERMINATION OF ANTIGLAUCOMA AGENTS | 2004 |
|
RU2365379C2 |
| TREATMENT OF EYE DISEASES SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH MEDICATIONS THAT ELIMINATE AGING CELLS | 2018 |
|
RU2815482C2 |
| GLAUCOMA TREATMENT | 2018 |
|
RU2759998C2 |
